Effects of two estroprogestins containing ethynilestradiol 30mug and drospirenone 3 mg and ethynilestradiol 30mug and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations
Authors:
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 24 (12) , 718-723
Abstract
Hyperandrogenic manifestation in women, such as seborrhea, acne and increased hair growth are common reasons of psychological distress. Skin appearance is very important for young women. This study evaluated the hormonal and skin effects of two estroprogestins (EPs) containing ethinyl-estradiol (EE) 30 μg associated with drospirenone (DRSP) 3 mg or chlormadinone acetate (CMA) 2 mg, respectively. Fifty-five women with signs and symptoms of hyperandrogenism (seborrhea, acne and increased hair growth) were enrolled in the study; randomly, 30 women were treated with EE 30 μg + DRSP 3 mg and 25 with EE 30 μg + CMA 2 mg. Follicle-stimulating hormone (FSH), luteinising hormone (LH), 17-hydroxyprogesterone (17OHP), androstenedione (A), testosterone (T), dehydroepiandrosterone sulfate (DHEAS), sex hormone binding globulin (SHBG) and free androgen index (T × 100/SHBG, FAI) were assessed at baseline, and after 3 and 6 months of treatment with EPs. Effects on seborrhea, acne and increased hair growth (as Ferriman-Gallwey score) were also evaluated at the same time points. Finally, skin hydration, transepidermal water loss (TEWL) and skin homogeneity were studied with non-invasive technique during the study. Treatment for 6 months with both EPs decreased significantly the circulating androgen levels (A, T, DHEAS) and FAI, and increased SHBG levels; also skin pattern was improved. EP containing EE and DRSP was better than EP containing EE and CMA as for skin changes, as seborrhea, acne, increased hair, hydration, homogeneity and overall quality of the skin; moreover, hormonal changes (as FAI) under therapy were more pronounced with EE/DRSP than EE/CMA. These effects may be considered in EP choice and could be important in improving patient's compliance and quality of life in hyperandrogenic women.Keywords
This publication has 19 references indexed in Scilit:
- Clinical and psychological correlates of quality-of-life in polycystic ovary syndromeEuropean Journal of Endocrinology, 2005
- Pharmacology of estrogens and progestogens: influence of different routes of administrationClimacteric, 2005
- Drospirenone in combination with estrogens: for contraception and hormone replacement therapyClimacteric, 2005
- Belara® – A reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoeaThe European Journal of Contraception & Reproductive Health Care, 2005
- Androgens and AntiandrogensAnnals of the New York Academy of Sciences, 2003
- Newer progestogensBMJ Sexual & Reproductive Health, 2003
- Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot studyMaturitas, 1995
- Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic ActivityAnnals of the New York Academy of Sciences, 1995
- The Effect of Oestrogenic Treatment on the Acid Mucopolysaccharide Pattern in Skin of MiceActa Pharmacologica et Toxicologica, 1972
- CLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMENThe Journal of Clinical Endocrinology & Metabolism, 1961